Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
Open Access
- 1 January 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Otolaryngology - Head & Neck Surgery
- Vol. 46 (1) , 58
Abstract
Background: Severe epistaxis is often difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). Propranolol has been shown to have antiangiogenic properties in vitro and in vivo and is commonly used to treat hemangiomas. We present our experience with topical nasal propranolol for the treatment of moderate to severe epistaxis in patients with HHT. Methods: Retrospective case series. Six patients with HHT were treated with 0.5 cm3 of 1.5% propranolol gel, applied to each nostril twice daily for at least 12 weeks. Outcome measures were epistaxis severity score (ESS), hemoglobin level, and number of blood transfusions prior to and while on treatment. Local and systemic side effects were recorded. Results: The mean duration of treatment was 30 ± 5.6 weeks. A significant improvement in the ESS was found in all patients, with a mean decrease from 6.4 ± 2.1 at treatment onset to 3.5 ± 1.7 at 12 weeks ( p = 0.028). Hemoglobin level increased significantly from 8.4 ± 3.1 to 11.0 ± 1.8 g/dL at 12 weeks ( p = 0.043). The mean number of blood transfusions decreased from 4.5 ± 4.9 before treatment to 2.5 ± 2.9 at 12 weeks and 0.3 ± 0.8 at 24 weeks, but the difference did not reach statistical significance ( p = 0.109 for both). No significant side effects of treatment were recorded. Conclusions: These preliminary results suggest that topical propranolol may be effective for the treatment of epistaxis in patients with HHT. A prospective controlled trial is required to confirm our findings.Keywords
This publication has 15 references indexed in Scilit:
- Anti-angiogenic therapeutic strategies in hereditary hemorrhagic telangiectasiaFrontiers in Genetics, 2015
- Optimal management of hereditary hemorrhagic telangiectasiaJournal of Blood Medicine, 2014
- Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double‐blind, randomized, placebo‐controlled trialHead & Neck, 2014
- Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variantsBMJ Case Reports, 2014
- Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasiaAmerican Journal of Otolaryngology, 2012
- Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac OutputJAMA, 2012
- Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasiaThrombosis and Haemostasis, 2012
- Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesisGenetics in Medicine, 2011
- Propranolol for infantile haemangiomas: insights into the molecular mechanisms of actionBritish Journal of Dermatology, 2010
- Local serum levels of vascular endothelial growth factor in infantile hemangioma: Intriguing mechanism of endothelial growthCytokine, 2010